EY Announces Drs. Stephanie and Eric Venn-Watson as Entrepreneur Of The Year® 2023 Pacific Southwest Award Finalists
Entrepreneur Of The Year celebrates ambitious entrepreneurs who are building bolder futures
SAN DIEGO, May 11, 2023 /PRNewswire-PRWeb/ -- Ernst & Young LLP (EY US) has named Drs. Stephanie and Eric Venn-Watson, the founders of Seraphina Therapeutics, as finalists for the Entrepreneur Of The Year® 2023 Pacific Southwest Award. This prestigious award recognizes transformative entrepreneurs and leaders of high-growth companies who are building a more equitable, sustainable, and prosperous world for all.
Drs. Stephanie and Eric Venn-Watson are being recognized for their groundbreaking discovery of C15:0 (pentadecanoic acid) as an essential fatty acid that has largely disappeared from the modern Western diet, and bringing it to market as a food fortifier and pure C15:0 nutritional supplement called fatty15.
Voluminous research supports that C15:0 has a positive impact on overall health. Today, it is hypothesized that C15:0 nutritional deficiencies are driving the rise in chronic diseases, including type 2 diabetes, heart disease, nonalcoholic fatty liver disease, and certain types of cancer. The Venn-Watsons are on a mission to help restore populationwide C15:0 levels and stem multiple chronic conditions.
"We are thrilled to be named as finalists for this prestigious award," said Dr. Eric Venn-Watson. "Our passion for improving global health has driven us to explore new frontiers in nutrition and we are honored to have our work recognized by Ernst & Young."
Since their initial discovery, C15:0 research has bloomed across the world. A meta-analysis co–authored by Harvard Medical School found that people with higher C15:0 levels have a lower risk of developing type 2 diabetes. This protective effect is believed to be due to C15:0's ability to improve glucose control and insulin sensitivity.
In addition to its potential for reducing the risk of diabetes, C15:0 has also been shown to have anti-cancer properties. Among numerous studies demonstrating C15:0's direct anti-cancer effects, C15:0 also improved upon gemcitabine's efficacy in stopping the growth of human breast, liver, lung, and pancreatic cancer cell lines. A recent meta-analysis concluded that only C15:0 (not omega 3 or other fatty acids) is associated with a lower risk of colorectal cancer.
Another meta-analysis, led by co-authors from Harvard University, found that people with higher C15:0 levels are less likely to develop heart disease. This benefit may be due to C15:0's broad anti-inflammatory activities, as well as its demonstrated ability to lower cholesterol and triglyceride levels in relevant models.
Given the volume of research around the significant health benefits associated with C15:0, the discovery of C15:0 as an essential fatty acid has the potential to lead to new insights into the role of nutrition in preventing and treating chronic diseases, and could ultimately help to improve public health on a global scale.
About Seraphina Therapeutics. Inc.
Seraphina Therapeutics, Inc. is a health and wellness company dedicated to advancing global health through the discovery of essential fatty acids and micronutrient therapeutics. Through rigorous breakthrough science, the company develops fatty acid supplements, food fortifiers, and nutritional interventions to strengthen cells, keep mitochondria working and advance cellular homeostasis to counter age-related breakdown. With its team of industry-leading scientists, Seraphina Therapeutics challenges long-held approaches to nutrition, enabling the creation of novel health products designed to support quality of life. For more information, please visit DiscoverC15.com and fatty15.com.
Media Contact
GR0 Agency, GR0, (310) 439-1887, [email protected]
SOURCE Seraphina Therapeutics
Share this article